Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

In the Limelight

February 19, 2018 0

The Week in Review #18 The Market - The stock market recuperated most of its losses …

Seattle Genetics and Pieris Pharmaceuticals: A Collaboration to Improve Cancer Immunotherapy

February 15, 2018 0

Seattle Genetics and Pieris pharmaceutical Collaboration Agreement Pieris Pharmaceuticals (PIRS) and Seattle Genetics (SGEN) signed a multi-program immuno-oncology collaboration …

An Early FDA Approval of Vertex’s Cystic Fibrosis Combo Symdeko

February 15, 2018 0

Expected or not, we believe that the news announcing that the U.S. Food and Drug Administration …

Nektar Therapeutics: The Best Example of the “Sell Good News” Reckless Habit

February 14, 2018 0

Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR) Announce Global Development & Commercialization Collaboration for Nektar’s Product …

A Wild Wild Week

February 12, 2018 0

The Week in Review #17 A Wild Wild Week - The stock market looked as if …

Private Lessons and More

February 9, 2018 0

Prohost Letter #417 Private Lessons - These lessons are overdue and we had to do this …

From Stanford: A Step on the Road Toward a Cancer Cure. From Theravance: a Worthwhile Co-Development Agreement with Janssen Biotech

February 7, 2018 0

A Stanford research team investigating a new immunotherapy approach, which consists of injecting tiny amounts of two immuno-stimulating …

The Undiagnosed Market Seizures

February 6, 2018 0

We postponed the Prohost Letter we planned to post this past Monday until the market’s fits come to …

Vertex: Next-Generation Correctors VX-659 and VX-445 for Triple Combinations Promise Significant Clinical Benefits for Around 90% of People with Cystic Fibrosis.

February 1, 2018 0

Vertex (VRTX) announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part …

The FDA Grants Breakthrough Therapy Designation for Balovaptan – Roche’s Product for Autism Spectrum Disorder (ASD)

January 30, 2018 0

Yes, the title is real and correct and the condition is ASD. The US Food and …

ChemoCentryx’s Pancreatic Cancer Product News and Other Important Facts

January 26, 2018 0

ChemoCentryx (CCXI) develops new drugs for inflammatory, autoimmune diseases and cancers. The firm’s approach comprises targeting the chemokine …

Amgen’s Migraine Drug Passes the Trial Tests with High Grades

January 23, 2018 0

Amgen (AMGN): Phase 3b results from LIBERTY study assessing the safety and efficacy of Aimovig™(erenumab) 140 mg in …

Celgene Acquires Juno Therapeutics at $9 Billion or $87 a Share. Why Array is Trading Around $15 in Premarket Today.

January 22, 2018 0

Celgene (CELG) and Juno (JUNO) announced the signing of a definitive merger agreement upon which Celgene has agreed to …

Acorda’s Attempted Rally. See Also: Amgen, Merck and AstraZeneca

January 19, 2018 0

Acorda (ACOR) stock was up around 10% reaching over $28 in premarket trading. The stock is trading …

Juno Therapeutics’ Stock Rally. Exelixis’ Successful Trial for Liver Cancer

January 17, 2018 0

Juno Therapeutics’ (JUNO) stock price orbited the moon after-hours trading yesterday, rising 45%, following a wall street …

Another Week of Outperformance

January 16, 2018 0

The Week in Review #16 More Exciting Rallies in Prohost Picks - The past week and …

Merck’s Good News. Checkpoint Inhibitors’ Revenues

January 16, 2018 0

Checkpoint inhibitors approved for a few firms as immunotherapy for cancer are increasingly demonstrating their superiority …

Vertex: Good News from Europe. Ablynx: Rejecting Novo Nordisk’s Aquisition Offers.

January 11, 2018 0

VERTEX From Europe, Vertex (VRTX) was informed that the European Commission has granted an extension of the Marketing …

The Year in Review Part 2

January 10, 2018 0

Prohost Letter #416 Part 2 2017 - A YEAR OF BREAKTHROUGH TECHNOLOGIES, BREAKTHROUGH PRODUCTS, IMPROVEMENTS ON …

Exelixis Strategy: Expanding the Pipeline with Novel Products

January 8, 2018 0

As part of its ongoing strategy to build an innovative pipeline beyond its two internally-discovered, commercially …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

In the Limelight

Seattle Genetics and Pieris Pharmaceuticals: A Collaboration to Improve Cancer Immunotherapy

An Early FDA Approval of Vertex’s Cystic Fibrosis Combo Symdeko

Nektar Therapeutics: The Best Example of the “Sell Good News” Reckless Habit

A Wild Wild Week

Private Lessons and More

From Stanford: A Step on the Road Toward a Cancer Cure. From Theravance: a Worthwhile Co-Development Agreement with Janssen Biotech

The Undiagnosed Market Seizures

Vertex: Next-Generation Correctors VX-659 and VX-445 for Triple Combinations Promise Significant Clinical Benefits for Around 90% of People with Cystic Fibrosis.

The FDA Grants Breakthrough Therapy Designation for Balovaptan – Roche’s Product for Autism Spectrum Disorder (ASD)

ChemoCentryx’s Pancreatic Cancer Product News and Other Important Facts

Amgen’s Migraine Drug Passes the Trial Tests with High Grades

Celgene Acquires Juno Therapeutics at $9 Billion or $87 a Share. Why Array is Trading Around $15 in Premarket Today.

Acorda’s Attempted Rally. See Also: Amgen, Merck and AstraZeneca

Juno Therapeutics’ Stock Rally. Exelixis’ Successful Trial for Liver Cancer

Another Week of Outperformance

Merck’s Good News. Checkpoint Inhibitors’ Revenues

Vertex: Good News from Europe. Ablynx: Rejecting Novo Nordisk’s Aquisition Offers.

The Year in Review Part 2

Exelixis Strategy: Expanding the Pipeline with Novel Products